News & Updates

COVID-19 pandemic has shortened life expectancy in 2020: study
COVID-19 pandemic has shortened life expectancy in 2020: study
09 Nov 2021 byStephen Padilla

Life expectancy has decreased during the COVID-19 pandemic, with more than 28 million excess life years of life lost in 2020 in 31 countries, according to a study, noting a higher rate in men than women.

COVID-19 pandemic has shortened life expectancy in 2020: study
09 Nov 2021
SG’s COVID-19 lockdown takes toll on older adults’ mental, financial wellbeing
SG’s COVID-19 lockdown takes toll on older adults’ mental, financial wellbeing
09 Nov 2021 byTristan Manalac

During Singapore’s coronavirus disease 2019 (COVID-19) lockdown, older adults experienced a decrease in depressive symptoms accompanied by growing feelings of loneliness and lower physical activity (PA), according to a recent study.

SG’s COVID-19 lockdown takes toll on older adults’ mental, financial wellbeing
09 Nov 2021
Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics
Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics
09 Nov 2021

Type 2 diabetes (T2D) patients exposed to hydrochlorothiazide for more than 2 years appear to be at higher risk of cutaneous squamous cell carcinoma (cSCC), as reported in a recent study.

Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics
09 Nov 2021
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021

Fatty acid synthase (FASN) is commonly expressed in operable triple-negative breast cancer (TNBC) and is associated with a poor prognosis, but omeprazole can hamper FASN activity, which may potentially boost the efficacy of neoadjuvant chemotherapy, according to the results of a phase II study.

Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021
Quadruple therapy with empagliflozin/dapagliflozin affords long-term glycaemic control
Quadruple therapy with empagliflozin/dapagliflozin affords long-term glycaemic control
08 Nov 2021